GENERATION BIO CO. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.1 USD | -2.52% |
|
+6.53% | +87.88% |
| Apr. 12 | Transcript : Generation Bio Co. - Special Call | |
| Mar. 07 | Needham Cuts Price Target on Generation Bio to $10 From $14, Maintains Buy Rating | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 5.59M | Sales 2025 * | 4.77M | Capitalization | 206M |
|---|---|---|---|---|---|
| Net income 2024 * | -86M | Net income 2025 * | -97M | EV / Sales 2024 * | 9.33 x |
| Net cash position 2024 * | 154M | Net cash position 2025 * | - | EV / Sales 2025 * | 43.2 x |
| P/E ratio 2024 * |
-2.22
x | P/E ratio 2025 * |
-2.38
x | Employees | 174 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Generation Bio Co.
More recommendations
More press releases
| 1 day | -2.52% | ||
| 1 week | +6.53% | ||
| Current month | +9.54% | ||
| 1 month | -28.74% | ||
| 3 months | +61.46% | ||
| 6 months | +164.96% | ||
| Current year | +87.88% |
1 week
2.95
3.54
1 month
2.704.09
Current year
1.624.65
1 year
0.866.98
3 years
0.8635.41
5 years
0.8655.72
10 years
0.8655.72
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 17-09-30 | |
Matthew Norkunas
DFI | Director of Finance/CFO | 46 | 20-07-21 |
Antoinette Paone
COO | Chief Operating Officer | 46 | 18-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jeff Jonas
BRD | Director/Board Member | 71 | 18-04-30 |
| Director/Board Member | 76 | 17-11-30 | |
Jason Rhodes
FOU | Founder | 54 | 15-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 3.1 | -2.52% | 58,899 |
| 24-05-07 | 3.18 | -5.07% | 146,158 |
| 24-05-06 | 3.35 | +5.68% | 247,769 |
| 24-05-03 | 3.17 | +1.93% | 63,938 |
| 24-05-02 | 3.11 | +6.87% | 410,903 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotes
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.1
USD
Average target price
7.5
USD
Spread / Average Target
+141.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +87.88% | 211M | |
| +2.93% | 106B | |
| +7.02% | 23.47B | |
| -14.60% | 21.9B | |
| -7.05% | 18.77B | |
| -38.55% | 17.85B | |
| -8.83% | 16.78B | |
| +5.51% | 14.41B | |
| +37.49% | 12.86B | |
| +329.39% | 8.78B |
- Stock Market
- Equities
- GBIO Stock